ECM
TERN

Endurant Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Endurant Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-135,994
Closed -$1.38M – 65
2022
Q4 		$1.38M Buy
+135,994
New +$905K 0.56% 32

Other funds holding TERN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Endurant Capital Management's TERN Position: Q1 2023 in Review

Endurant Capital Management sold out of Terns Pharmaceuticals (TERN) in Q1 2023, closing a stake of 135,994 shares — an estimated $1.38M sold.

Endurant Capital Management first reported a position in TERN in Q4 2022 and held it in 1 quarter. The position peaked at $1.38M in Q4 2022. 78 funds tracked by Wall St. Rank hold TERN as of Q1 2023.

  • Endurant Capital Management reported no remaining Terns Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Endurant Capital Management sold 135,994 Terns Pharmaceuticals shares in Q1 2023, an estimated $1.38M.
  • Endurant Capital Management first reported a position in Terns Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Endurant Capital Management's Terns Pharmaceuticals position peaked at $1.38M in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2023.

Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.